Translational Biomarkers, In Vitro and In Vivo

Methods in Pharmacology and Toxicology

Volumn 2014, Issue , 2014, Pages 459-478

  Wilmes, Anja ^a   Limonciel, Alice ^a   Leonard, Martin O ^a   Jennings, Paul ^a  

^a NONE

Author keywords

Biomarkers; In vitro; Inflammation; Leakage; miRNA; Stress response

Indexed keywords

EID: 84930762298     PISSN: 15572153     EISSN: 19406053     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0521-8_20     Document Type: Article

References (123)

1. White WI (1991) A new look at the role of urinalysis in the history of diagnostic medicine. Clin Chem 37(1):119–125
2. Amacher DE (1998) Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 27(2):119–130. doi:10.1006/rtph.1998.1201
3. Brooks JD (2012) Translational genomics: the challenge of developing cancer biomarkers. Genome Res 22(2):183–187. doi:10.1101/gr.124347.111
4. Kumler I, Tuxen MK, Nielsen DL (2013) A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. doi:10.1016/j.ctrv.2013.09.002
5. Begg TB, Hill ID, Nickolls LC (1964) Breathalyzer and Kitagawa-Wright methods of measuring breath alcohol. Br Med J 1(5374):9–15
6. Zhou L, Zhao SZ, Koh SK, Chen L, Vaz C, Tanavde V, Li XR, Beuerman RW (2012) In-depth analysis of the human tear proteome. J Proteomics 75(13):3877–3885. doi:10.1016/j.jprot.2012.04.053
7. Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J (2010) TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Cancer Epidemiol Biomarkers Prev 19(1):182–195. doi:10.1158/1055-9965.EPI-09-0162
8. Bijuklic K, Jennings P, Kountchev J, Hasslacher J, Aydin S, Sturn D, Pfaller W, Patsch JR, Joannidis M (2007) Migration of leukocytes across an endothelium-epithelium bilayer as a model of renal interstitial inflammation. Am J Physiol Cell Physiol 293(1): C486–C492. doi:10.1152/ajpcell.00419.2006
9. Aydin S, Signorelli S, Lechleitner T, Joannidis M, Pleban C, Perco P, Pfaller W, Jennings P (2008) Influence of microvascular endothelial cells on transcriptional regulation of proximal tubular epithelial cells. Am J Physiol Cell Physiol 294(2):C543–C554. doi:10.1152/ajpcell.00307.2007
10. Bijuklic K, Sturn DH, Jennings P, Kountchev J, Pfaller W, Wiedermann CJ, Patsch JR, Joannidis M (2006) Mechanisms of neutrophil transmigration across renal proximal tubular HK-2 cells. Cell Physiol Biochem 17(5–6):233–244. doi:10.1159/000094128
11. Zurich MG, Stanzel S, Kopp-Schneider A, Prieto P, Honegger P (2013) Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. Toxicol In vitro 27(4):1416–1424. doi:10.1016/j. tiv.2012.06.018
12. Limonciel A, Aschauer L, Wilmes A, Prajczer S, Leonard MO, Pfaller W, Jennings P (2011) Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes. Toxicol In vitro 25(8):1855–1862. doi:10.1016/j.tiv.2011.05.018
13. Wilmes A, Limonciel A, Aschauer L, Moenks K, Bielow C, Leonard MO, Hamon J, Carpi D, Ruzek S, Handler A, Schmal O, Herrgen K, Bellwon P, Burek C, Truisi GL, Hewitt P, Di Consiglio E, Testai E, Blaauboer BJ, Guillou C, Huber CG, Lukas A, Pfaller W, Mueller SO, Bois FY, Dekant W, Jennings P (2013) Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics 79:180–194. doi:10.1016/j.jprot.2012.11.022
14. Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie D, Chibout SD, Vonderscher J, Maurer G (2010) Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 28(5):463–469. doi:10.1038/nbt.1622
15. FDA (2009) Guidance for industry drug-induced liver injury: premarketing clinical evaluation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Accessed Dec 2013.
16. Limonciel A, Wilmes A, Aschauer L, Radford R, Bloch KM, McMorrow T, Pfaller W, van Delft JH, Slattery C, Ryan MP, Lock EA, Jennings P (2012) Oxidative stress induced by potassium bromate exposure results in altered tight junction protein expression in renal proximal tubule cells. Arch Toxicol 86(11):1741–1751. doi:10.1007/s00204-012-0897-0
17. Lechner J, Malloth N, Seppi T, Beer B, Jennings P, Pfaller W (2008) IFN-alpha induces barrier destabilization and apoptosis in renal proximal tubular epithelium. Am J Physiol Cell Physiol 294(1):C153–C160. doi:10.1152/ajpcell.00120.2007
18. Novellino A, Scelfo B, Palosaari T, Price A, Sobanski T, Shafer TJ, Johnstone AF, Gross GW, Gramowski A, Schroeder O, Jugelt K, Chiappalone M, Benfenati F, Martinoia S, Tedesco MT, Defranchi E, D'Angelo P, Whelan M (2011) Development of microelectrode array based tests for neurotoxicity: assessment of interlaboratory reproducibility with neuroactive chemicals. Front Neuroeng 4:4. doi:10.3389/fneng.2011.00004
19. Jonsson MK, Wang QD, Becker B (2011) Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay Drug Dev Technol 9(6):589–599. doi:10.1089/adt.2011.0396
20. Xi B, Wang T, Li N, Ouyang W, Zhang W, Wu J, Xu X, Wang X, Abassi YA (2011) Functional cardiotoxicity profiling and screening using the xCELLigence RTCA cardio system. J Lab Autom 16(6):415–421. doi:10.1016/j.jala.2011.09.002
21. Marrer E, Dieterle F (2010) Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol 243(2):167–179. doi:10.1016/j.taap.2009.12.015
22. Amacher DE (2010) The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol 245(1):134–142. doi:10.1016/j.taap.2010.02.011
23. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245(3):194–205. doi:10.1016/j. tox.2007.11.021
24. Chouker A, Martignoni A, Schauer RJ, Dugas M, Schachtner T, Kaufmann I, Setzer F, Rau HG, Lohe F, Jauch KW, Peter K, Thiel M (2005) Alpha-glutathione S-transferase as an early marker of hepatic ischemia/ reperfusion injury after liver resection. World J Surg 29(4):528–534. doi:10.1007/s00268-004-7431-3
25. Branten AJ, Mulder TP, Peters WH, Assmann KJ, Wetzels JF (2000) Urinary excretion of glutathione S transferases alpha and pi in patients with proteinuria: reflection of the site of tubular injury. Nephron 85(2):120–126, doi:45644
26. Koleva M (1977) Changes in the urinary excretion of gamma-glutamyltranspeptidase, leucine aminopeptidase and alkaline phosphatase in the combined action of ethylene glycol and high temperature. Probl Khig 3: 35–46
27. Pfaller W, Thorwartl U, Nevinny-Stickel M, Krall M, Schober M, Joannidis M, Hobisch A (1994) Clinical value of fructose 1,6 bisphosphatase in monitoring renal proximal tubular injury. Kidney Int Suppl 47:S68–S75
28. Wellwood JM, Davies D, Leighton M, Thompson AE (1978) Urinary N-acetylbetaD-glucosaminidase assay in renal transplant recipients. Transplantation 26(6):396–400
29. Babuin L, Jaffe AS (2005) Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 173(10):1191–1202. doi:10.1503/cmaj/051291
30. van der Harst MR, Bull S, Laffont CM, Klein WR (2005) Gentamicin nephrotoxicity–a comparison of in vitro findings with in vivo experiments in equines. Vet Res Commun 29(3):247–261
31. Senthil Kumar KJ, Liao JW, Xiao JH, Gokila Vani M, Wang SY (2012) Hepatoprotective effect of lucidone against alcohol-induced oxidative stress in human hepatic HepG2 cells through the up-regulation of HO-1/Nrf-2 antioxidant genes. Toxicol In Vitro 26(5): 700–708. doi:10.1016/j.tiv.2012.03.012
32. Jennings P, Koppelstaetter C, Pfaller W, Morin JP, Hartung T, Ryan MP (2004) Assessment of a new cell culture perfusion apparatus for in vitro chronic toxicity testing. Part 2: toxicological evaluation. ALTEX 21(2):61–66
33. Miret S, De Groene EM, Klaffke W (2006) Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2. J Biomol Screen 11(2):184–193. doi:10.1177/1087057105283787
34. Jennings P, Limonciel A, Felice L, Leonard MO (2013) An overview of transcriptional regulation in response to toxicological insult. Arch Toxicol 87(1):49–72. doi:10.1007/s00204-012-0919-y
35. Zager RA, Johnson AC, Becker K (2012) Plasma and urinary heme oxygenase-1 in AKI. J Am Soc Nephrol 23(6):1048–1057. doi:10.1681/ASN.2011121147
36. Wilmes A, Crean D, Aydin S, Pfaller W, Jennings P, Leonard MO (2011) Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicol In Vitro 25(3): 613–622. doi:10.1016/j.tiv.2010.12.009
37. Russmann S, Kullak-Ublick GA, Grattagliano I (2009) Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16(23):3041–3053
38. Kaplowitz N (2001) Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 24(7):483–490
39. Stevens JL, Baker TK (2009) The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 14(3–4): 162–167. doi:10.1016/j.drudis.2008.11.009
40. Vinken M, Maes M, Vanhaecke T, Rogiers V (2013) Drug-induced liver injury: mechanisms, types and biomarkers. Curr Med Chem 20(24):3011–21
41. Majumdar M, Ratho R, Chawla Y, Singh MP (2013) High levels of circulating HMGB1 as a biomarker of acute liver failure in patients with viral hepatitis E. Liver Int 33(9):1341– 1348. doi:10.1111/liv.12197
42. Oshima G, Shinoda M, Tanabe M, Ebinuma H, Nishiyama R, Takano K, Yamada S, Miyasho T, Masugi Y, Matsuda S, Suda K, Fukunaga K, Matsubara K, Hibi T, Yagi H, Hayashida T, Yamagishi Y, Obara H, Itano O, Takeuchi H, Kawachi S, Saito H, Hibi T, Maruyama I, Kitagawa Y (2012) Increased plasma levels of high mobility group box 1 in patients with acute liver failure. Eur Surg Res 48(3):154–162. doi:10.1159/000338363
43. Erlandsson Harris H, Andersson U (2004) Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34(6):1503–1512. doi:10.1002/eji.200424916
44. Seo YS, Kwon JH, Yaqoob U, Yang L, de Assuncao TM, Simonetto DA, Verma VK, Shah VH (2013) HMGB1 recruits hepatic stellate cells and liver endothelial cells to sites of ethanol induced parenchymal cell injury. Am J Physiol Gastrointest Liver Physiol. doi:10.1152/ajpgi.00151.2013
45. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2):79–87. doi:10.1016/j.tcb.2005.12.005
46. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5–6): 333–345. doi:10.1016/j.cytogfr.2008.08.001
47. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, Ge X, Fiel MI, Nieto N (2012) Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin alpha(V)beta(3) engagement and PI3K/ pAkt/NFkappaB signaling. Hepatology 55(2):594–608. doi:10.1002/hep.24701
48. He CY, Liang BB, Fan XY, Cao L, Chen R, Guo YJ, Zhao J (2012) The dual role of osteopontin in acetaminophen hepatotoxicity. Acta Pharmacol Sin 33(8):1004–1012. doi:10.1038/aps.2012.47
49. Ramaiah SK, Rittling S (2007) Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury. Expert Opin Drug Metab Toxicol 3(4):519–526. doi:10.1517/17425225.3.4.519
50. Fujisawa K, Yabuuchi C, Izawa T, Kuwamura M, Takasu N, Torii M, Yamate J (2013) Expression patterns of heat shock protein 25 in carbon tetrachloride-induced rat liver injury. Exp Toxicol Pathol 65(5):469–476. doi:10.1016/j.etp.2012.02.001
51. Kawashima R, Mochida S, Matsui A, YouLuTu ZY, Ishikawa K, Toshima K, Yamanobe F, Inao M, Ikeda H, Ohno A, Nagoshi S, Uede T, Fujiwara K (1999) Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 256(3):527–531. doi:10.1006/bbrc.1999.0372
52. Guo H, Marroquin CE, Wai PY, Kuo PC (2005) Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells. Dig Dis Sci 50(7):1288–1298
53. Zhang G, Huang Z, Shi R, Lin Y, Hao B (2006) Osteopontin regulation by protein kinase B (Akt) in HepG2 cells. Exp Oncol 28(1):36–39
54. Xia Y, Chen R, Song Z, Ye S, Sun R, Xue Q, Zhang Z (2010) Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum. J Cancer Res Clin Oncol 136(2): 309–321. doi:10.1007/s00432-009-0666-5
55. Moll R (1991) Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochem Suppl 41: 117–127
56. Rydlander L, Ziegler E, Bergman T, Schoberl E, Steiner G, Bergman AC, Zetterberg A, Marberger M, Bjorklund P, Skern T, Einarsson R, Jornvall H (1996) Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 241(2):309–314
57. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187(5):567–572. doi:10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J
58. Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, Aderaye G, Lindquist L, Mattsson CM, Ekblom B, Antoine DJ, Park BK, Linder S, Harrill AH, Watkins PB, Glinghammar B, Schuppe-Koistinen I (2013) Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for druginduced liver injury in two human cohorts. Liver Int. doi:10.1111/liv.12322
59. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50(4):1072–1078. doi:10.1002/hep.23050
60. John K, Wielgosz S, Schulze-Osthoff K, Bantel H, Hass R (2013) Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome. Cell Death Dis 4:e886. doi:10.1038/cddis. 2013.408
61. Parfieniuk-Kowerda A, Lapinski TW, Rogalska-Plonska M, Swiderska M, Panasiuk A, Jaroszewicz J, Flisiak R (2013) Serum cytochrome c and m30-neoepitope of cytokeratin18 in chronic hepatitis C. Liver Int. doi:10.1111/liv.12297
62. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Yerci O, Oral AY, Gul CB, Gurel S, Nak SG, Gulten M (2009) Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit 15(4):CR189–CR193
63. Hetz H, Hoetzenecker K, Hacker S, Faybik P, Pollreisz A, Moser B, Roth G, Hoetzenecker W, Lichtenauer M, Klinger M, Krenn CG, Ankersmit HJ (2007) Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. J Clin Lab Anal 21(5):277–281. doi:10.1002/jcla.20180
64. Jones SE, Jomary C (2002) Clusterin. Int J Biochem Cell Biol 34(5):427–431
65. Aulitzky WK, Schlegel PN, Wu DF, Cheng CY, Chen CL, Li PS, Goldstein M, Reidenberg M, Bardin CW (1992) Measurement of urinary clusterin as an index of nephrotoxicity. Proc Soc Exp Biol Med 199(1):93–96
66. Correa-Rotter R, Ibarra-Rubio ME, Schwochau G, Cruz C, Silkensen JR, Pedraza-Chaverri J, Chmielewski D, Rosenberg ME (1998) Induction of clusterin in tubules of nephrotic rats. J Am Soc Nephrol 9(1): 33–37
67. Rached E, Hoffmann D, Blumbach K, Weber K, Dekant W, Mally A (2008) Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Toxicol Sci 103(2):371–381. doi:10.1093/toxsci/kfn040
68. Ishii A, Sakai Y, Nakamura A (2007) Molecular pathological evaluation of clusterin in a rat model of unilateral ureteral obstruction as a possible biomarker of nephrotoxicity. Toxicol Pathol 35(3):376–382. doi:10.1080/01926230701230320
69. Sohn SJ, Kim SY, Kim HS, Chun YJ, Han SY, Kim SH, Moon A (2013) In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells. Toxicol Lett 217(3):235–242. doi:10.1016/j. toxlet.2012.12.015
70. Girton RA, Sundin DP, Rosenberg ME (2002) Clusterin protects renal tubular epithelial cells from gentamicin-mediated cytotoxicity. Am J Physiol Renal Physiol 282(4):F703–F709. doi:10.1152/ajprenal.00060.2001
71. Dinarello CA, Novick D, Kim S, Kaplanski G (2013) Interleukin-18 and IL-18 binding protein. Front Immunol 4:289. doi:10.3389/fimmu.2013.00289
72. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL (2004) Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43(3):405–414
73. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL (2005) Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 16(10):3046–3052. doi:10.1681/ASN.2005030236
74. Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR (2010) IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 21(1): 189–197. doi:10.1681/ASN.2009030264
75. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, Jiaqi Q (2008) Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 108(3):c176–c181.doi:10.1159/000117814
76. Miyauchi K, Takiyama Y, Honjyo J, Tateno M, Haneda M (2009) Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract 83(2):190–199. doi:10.1016/j.diabres.2008.11.018
77. Xu SY, Carlson M, Engstrom A, Garcia R, Peterson CG, Venge P (1994) Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest 54(5):365–376
78. Kieran NE, Doran PP, Connolly SB, Greenan MC, Higgins DF, Leonard M, Godson C, Taylor CT, Henger A, Kretzler M, Burne MJ, Rabb H, Brady HR (2003) Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int 64(2):480–492. doi:10.1046/j.1523-1755.2003.00106.x
79. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14(10):2534–2543
80. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW (2006) Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 103(6): 1834–1839. doi:10.1073/pnas.0510847103
81. Zhao P, Stephens JM (2013) STAT1, NF-kappaB and ERKs play a role in the induction of lipocalin-2 expression in adipocytes. Mol Metab 2(3):161–170. doi:10.1016/j. molmet.2013.04.003
82. Makris K, Rizos D, Kafkas N, Haliassos A (2012) Neurophil gelatinase-associated lipocalin as a new biomarker in laboratory medicine. Clin Chem Lab Med 50(9):1519–1532. doi:10.1515/cclm-2012-0227
83. Bach PH, Nguyen TK (1998) Renal papillary necrosis–40 years on. Toxicol Pathol 26(1):73–91
84. Hildebrand H, Rinke M, Schluter G, Bomhard E, Falkenberg FW (1999) Urinary antigens as markers of papillary toxicity. II: Application of monoclonal antibodies for the determination of papillary antigens in rat urine. Arch Toxicol 73(4–5):233–245
85. Pinches M, Betts C, Bickerton S, Burdett L, Thomas H, Derbyshire N, Jones HB, Moores M (2012) Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences. Toxicol Pathol 40(3):522–533. doi:10.1177/0192623311432438
86. Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R (2013) Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther 138(3):470– 484. doi:10.1016/j.pharmthera.2013.03.005
87. Gerszten RE, Asnani A, Carr SA (2011) Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res 109(4):463–474. doi:10.1161/CIRCRESAHA.110.225003
88. Halade GV, Jin YF, Lindsey ML (2013) Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 139(1):32–40. doi:10.1016/j.pharmthera.2013.03.009
89. Tseng HC, Lee IT, Lin CC, Chi PL, Cheng SE, Shih RH, Hsiao LD, Yang CM (2013) IL-1beta promotes corneal epithelial cell migration by increasing MMP-9 expression through NF-kappaB-and AP-1-dependent pathways. PLoS One 8(3):e57955. doi:10.1371/journal.pone.0057955
90. Gordon GM, Ledee DR, Feuer WJ, Fini ME (2009) Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. J Cell Physiol 221(2):402–411. doi:10.1002/jcp.21869
91. Awad AE, Kandalam V, Chakrabarti S, Wang X, Penninger JM, Davidge ST, Oudit GY, Kassiri Z (2010) Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol 298(3):C679–C692. doi:10.1152/ajpcell.00351.2009
92. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PW, Vasan RS (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109(23):2850–2856.doi: 10.1161/01. CIR.0000129318. 79570.84
93. Vorovich EE, Chuai S, Li M, Averna J, Marwin V, Wolfe D, Reilly MP, Cappola TP (2008) Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure. Am Heart J 155(6): 992–997. doi:10.1016/j.ahj.2008.01.007
94. Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45–79. doi:10.1146/annurev. physiol.65.092101.142243
95. Latini R, Masson S, de Angelis N, Anand I (2002) Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. J Card Fail 8(5): 288–299
96. Bistola V, Nikolopoulou M, Derventzi A, Kataki A, Sfyras N, Nikou N, Toutouza M, Toutouzas P, Stefanadis C, Konstadoulakis MM (2008) Long-term primary cultures of human adult atrial cardiac myocytes: cell viability, structural properties and BNP secretion in vitro. Int J Cardiol 131(1):113–122. doi:10.1016/j.ijcard.2007.10.058
97. Harada M, Saito Y, Kuwahara K, Ogawa E, Ishikawa M, Nakagawa O, Miyamoto Y, Kamitani S, Hamanaka I, Kajiyama N, Takahashi N, Masuda I, Itoh H, Nakao K (1998) Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol 31(Suppl 1):S357–S359
98. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR, Fahy JV (2007) Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 104(40):15858–15863. doi:10.1073/pnas.0707413104
99. Parulekar AD, Atik MA, Hanania NA (2013) Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med. doi:10.1097/MCP.0000000000000005
100. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365(12):1088–1098. doi:10.1056/NEJMoa1106469
101. Chan YC, Banerjee J, Choi SY, Sen CK (2012) miR-210: the master hypoxamir. Microcirculation 19(3):215–223. doi:10.1111/j.1549-8719.2011.00154.x
102. Magenta A, Greco S, Gaetano C, Martelli F (2013) Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci 14(9):17319– 17346. doi:10.3390/ijms140917319
103. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A (2014) Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol 44(1):53– 58. doi:10.3892/ijo.2013.2169
104. Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O (2013) MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol 34(1):481–491. doi:10.1007/s13277-012-0573-2
105. Lorenzen JM, Volkmann I, Fiedler J, Schmidt M, Scheffner I, Haller H, Gwinner W, Thum T (2011) Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 11(10):2221–2227. doi:10.1111/j.1600-6143.2011.03679.x
106. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM (2004) miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1(2):106–113
107. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3(2):87–98. doi:10.1016/j.cmet.2006.01.005
108. Cui L, Shi Y, Zhou X, Wang X, Wang J, Lan Y, Wang M, Zheng L, Li H, Wu Q, Zhang J, Fan D, Han Y (2013) A set of microRNAs mediate direct conversion of human umbilical cord lining-derived mesenchymal stem cells into hepatocytes. Cell Death Dis 4:e918. doi:10.1038/cddis.2013.429
109. Deng XG, Qiu RL, Wu YH, Li ZX, Xie P, Zhang J, Zhou JJ, Zeng LX, Tang J, Maharjan A, Deng JM (2013) Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-122/FoxA1/HNF4a-positive feedback loop. Liver Int. doi:10.1111/liv.12239
110. Doddapaneni R, Chawla YK, Das A, Kalra JK, Ghosh S, Chakraborti A (2013) Overexpression of microRNA-122 enhances in vitro hepatic differentiation of fetal liver-derived stem/progenitor cells. J Cell Biochem 114(7):1575–1583. doi:10.1002/jcb.24499
111. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106(11):4402– 4407. doi:10.1073/pnas.0813371106
112. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54(5):1767–1776. doi:10.1002/hep.24538
113. Nabialek E, Wanha W, Kula D, Jadczyk T, Krajewska M, Kowalowka A, Dworowy S, Hrycek E, Wludarczyk W, Parma Z, Michalewska-Wludarczyk A, Pawlowski T, Ochala B, Jarzab B, Tendera M, Wojakowski W (2013) Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease. Minerva Cardioangiol 61(6):627–637
114. Sayed AS, Xia K, Yang TL, Peng J (2013) Circulating microRNAs: a potential role in diagnosis and prognosis of acute myocardial infarction. Dis Markers 35(5):561–566. doi:10.1155/2013/217948
115. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF (2006) Myogenic factors that regulate expression of musclespecific microRNAs. Proc Natl Acad Sci U S A 103(23):8721–8726. doi:10.1073/pnas.0602831103
116. Huang F, Tang L, Fang ZF, Hu XQ, Pan JY, Zhou SH (2013) miR-1-mediated induction of cardiogenesis in mesenchymal stem cells via downregulation of Hes-1. BioMed Res Int 2013:216286. doi:10.1155/2013/216286
117. Chen T, Ding G, Jin Z, Wagner MB, Yuan Z (2012) Insulin ameliorates miR-1-induced injury in H9c2 cells under oxidative stress via Akt activation. Mol Cell Biochem 369(1–2): 167–174. doi:10.1007/s11010-012-1379-7
118. Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu JN, Liu XY, Zhang YY, Li Y, Lin SG, Yu XY (2009) Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 381(4):597–601. doi:10.1016/j. bbrc.2009.02.097
119. Bostjancic E, Zidar N, Stajner D, Glavac D (2010) MicroRNA miR-1 is up-regulated in remote myocardium in patients with myocardial infarction. Folia Biol 56(1):27–31
120. Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, Dong X, Qin S, Zhang C (2010) A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 119(2):87–95. doi:10.1042/CS20090645
121. Zhou X, Mao A, Wang X, Duan X, Yao Y, Zhang C (2013) Urine and serum microRNA-1 as novel biomarkers for myocardial injury in open-heart surgeries with cardiopulmonary bypass. PLoS One 8(4):e62245. doi:10.1371/journal.pone.0062245
122. Ellis JK, Athersuch TJ, Cavill R, Radford R, Slattery C, Jennings P, McMorrow T, Ryan MP, Ebbels TM, Keun HC (2011) Metabolic response to low-level toxicant exposure in a novel renal tubule epithelial cell system. Mol Biosyst 7(1):247–257. doi:10.1039/c0mb00146e
123. Aschauer L, Gruber LN, Pfaller W, Limonciel A, Athersuch TJ, Cavill R, Khan A, Gstraunthaler G, Grillari J, Grillari R, Hewitt P, Leonard MO, Wilmes A, Jennings P (2013) Delineation of the key aspects in the regulation of epithelial monolayer formation. Mol Cell Biol 33(13):2535–2550. doi:10.1128/MCB.01435-12